# A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)

> **NCT00719472** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 451 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)
- **DRUG:** CVP (cyclophosphamide, vincristine, prednisone)
- **DRUG:** Analgesic/antipyretic and antihistamine drugs

## Key facts

- **NCT ID:** NCT00719472
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 451 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00719472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00719472, "A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00719472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*